Self-sealing male Luer connector with molded elastomeric tip

Details for Australian Patent Application No. 2005284825 (hide)

Owner CareFusion 303, Inc.

Inventors Phillips, John C.

Agent Griffith Hack

Pub. Number AU-B-2005284825

PCT Pub. Number WO2006/031958

Priority 10/941,550 15.09.04 US

Filing date 14 September 2005

Wipo publication date 23 March 2006

Acceptance publication date 24 November 2011

International Classifications

A61M 39/26 (2006.01) Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use

F16L 37/28 (2006.01) Couplings of the quick-acting type - with fluid cut-off means

Event Publications

19 April 2007 PCT application entered the National Phase

  PCT publication WO2006/031958 Priority application(s): WO2006/031958

11 February 2010 Alteration of Name

  The name of the applicant has been altered to CareFusion 303, Inc.

24 November 2011 Application Accepted

  Published as AU-B-2005284825

16 February 2012 Application for Amendment

  The nature of the amendment is as shown in the statement(s) filed 20 Jan 2012. Address for service in Australia - Griffith Hack Level 10 167 Eagle Street Brisbane QLD 4001

7 June 2012 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 20 Jan 2012

14 June 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005284826-Process for the preparation of 6, 8-substituted `1, 7 naphthpyridin derivatives by reacting the 8-halo-`1, 7 naphthpyridin-derivate with an organic boronic acid derivatives and intermadiates of this process

2005284822-Method for treatment with bucindolol based on genetic targeting